ABBV Stock UPDATES Abbvie Inc. Common Stock (ABBV) 56.95 09/09/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Abbvie Inc. Common Stock (ABBV) 56.95 $ABBV

Roche's (RHHBY) RoActemra Gets EU Approval for Early RA - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 09, 4:20PM CDT
Positive news flowed in at Roche (RHHBY) when its RA drug RoActemra received approval from the European Commission to treat patients suffering from early RA who have previously not been treated with methotrexate (MTX).

AbbVie (ABBV) Marked As A Barbarian At The Gate
at The Street - Tue Sep 09, 12:23PM CDT
Trade-Ideas LLC identified AbbVie (ABBV) as a "barbarian at the gate" (strong stocks crossing above resistance with today's range greater than 200%) candidate

Uveitis Therapeutics Pipeline Review, H2 2014 - 19 Companies & 30 Drug Profiles
M2 - Tue Sep 09, 8:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/cv63wn/uveitis) has announced the addition of the "Uveitis - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Uveitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Uveitis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - pSivida Corp. - Advanced Cell Technology, Inc. - Santen Pharmaceutical Co., Ltd. - Apitope International NV - Novartis AG - Pfizer Inc. - Enzo Biochem, Inc. - Can-Fite BioPharma Ltd. - XOMA Corporation - HanAll Biopharma Co., Ltd. - TxCell SA - Endocyte, Inc. - to-BBB technologies BV - Janssen Biotech, Inc. - Icon Bioscience, Inc. - Eleven Biotherapeutics - AbbVie Inc. - OncoNOx ApS - Panoptes Pharma Ges.m.b.H. Drug Profiles - sirolimus - adalimumab - fluocinolone acetonide - gevokizumab - secukinumab - CF-101 - triamcinolone acetonide - LFG-316 - B27-PD - triamcinolone acetonide - celecoxib - HL-036 - EC-1496 - PA-2612 - 2B3-201 - ATX-UV1 - ATX-UV2 - Stem Cell Therapy for Ophthalmic and Autoimmune Diseases - OX-1001 - P-13 - IBI-70090 - plastoquinone decyl triphenylphosphonium bromide - EC-1669 - lodamin - PP-001 - INV-17 - EBI-028 - Col-Treg - Small Molecules to Inhibit Kinase for Uveitis and IBD - Drugs to Inhibit Aldose Reductase for Immunology, Ophthalmology, Metabolic, Respiratory and Autoimmune Disorders For more information visit http://www.researchandmarkets.com/research/cv63wn/uveitis

Pharmacyclics Price Target Cut On Higher Spending
at Investor's Business Daily - Mon Sep 08, 12:02PM CDT
Biotech Pharmacyclics (PCYC) got a price-target cut from Nomura on Monday, but the investment bank maintained a buy rating on Pharmacyclics stock, saying the company's competitive position remains strong. Pharmacyclics stock was flat in midday...

FTC Sues Pharmaceutical Companies for Illegally Blocking Consumer Access to Lower-Cost Versions of the Blockbuster Drug AndroGel
PR Newswire - Mon Sep 08, 11:50AM CDT
In its latest action to ensure competition in the nation's healthcare markets, the Federal Trade Commission has filed a complaint in federal district court charging several major pharmaceutical companies with illegally blocking American consumers' access to lower-cost versions of the blockbuster drug AndroGel.

Will Google and AbbVie’s $1.5 Billion Anti-Aging Partnership Pay Off?
Leo Sun, The Motley Fool - Motley Fool - Sat Sep 06, 6:05AM CDT
Google 's health care footprint just got a lot bigger, thanks to a new $1.5 billion partnership between its biotech unit Calico and drug maker AbbVie . Source: Wikimedia Commons. Calico, which is headed by former Genentech CEO Arthur...

Abbott Labs' FreeStyle Libre Flash Glucose Gets CE Mark - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Sep 05, 3:35PM CDT
Abbott Labs (ABT) received positive news when its FreeStyle Libre Flash Glucose Monitoring System obtained CE Mark (Conformite Europeenne) in Europe.

Why Gilead Is Falling On Drugs For Developing Nations
at Investor's Business Daily - Fri Sep 05, 2:15PM CDT
Shares of Gilead Sciences (GILD) are down amid news that the drugmaker is reportedly nearing a licensing deal to bring its blockbuster hepatitis C drug Sovaldi to developing countries such as India and Pakistan. Generic drugmakers would be able to...

Treasury Secretary's Upcoming Inversion Talk to Widen Spreads
at The Street - Fri Sep 05, 8:21AM CDT
The Treasury Secretary Jack Lew is expected to opine on tax inversions next week, a subject that has been a major issue for risk arbitrage spreads.

AbbVie to Present at Morgan Stanley Global Healthcare Conference
PR Newswire - Fri Sep 05, 7:00AM CDT
AbbVie (NYSE: ABBV) will participate in the Morgan Stanley Global Healthcare Conference on Wednesday, Sept. 10, 2014. Bill Chase, executive vice president and chief financial officer, will make a formal presentation on the company at 9:20 a.m. Central time.

Will AbbVie's $805 Million Agreement for Duvelisib Pay Off? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 04, 4:10PM CDT
In order to boost its pipeline, AbbVie (ABBV) inked a collaboration agreement with Infinity Pharmaceuticals (INFI).

3 Reasons Bristol-Myers Squibb's Stock Could Fall
George Budwell, The Motley Fool - Motley Fool - Thu Sep 04, 3:42PM CDT
This has been a year of major changes for Big Pharma. As the so-called patent cliff has started to peak, we've seen a number of companies make huge acquisitions, push promising new drugs into regulatory review, and even move to change locales to...

Google's Calico in $500M Joint Venture with AbbVie - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 04, 3:38PM CDT
Calico, Google's (GOOGL) year-old health startup is collaborating with biotechnology drugmaker, AbbVie, a spin-off from Abbott Laboratories (ABT), for a joint venture to formulate treatments for cancer and Alzheimer's.

Upcoming Event, Drug Approval, Technical Updates, and Research Grant - Research Reports on Gilead, Pfizer, AbbVie, Express Scripts and Thermo Fisher
PR Newswire - Thu Sep 04, 8:20AM CDT
Today, Analysts Review released its research reports regarding Gilead Sciences, Inc. (NASDAQ: GILD), Pfizer Inc. (NYSE: PFE), AbbVie Inc. (NYSE: ABBV), Express Scripts Holding Company (NASDAQ: ESRX) and Thermo Fisher Scientific Inc. (NYSE: TMO). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6210-100free.

3 Reasons Gilead Sciences, Inc.’s Stock Could Fall
Brian Orelli, The Motley Fool - Motley Fool - Thu Sep 04, 7:31AM CDT
Gilead Sciences ' stock is a trading at all-time highs, up more than 80% over the last year on the back of a very successful launch of the company's hepatitis C drug Sovaldi. A few weeks ago, I shared three reasons Gilead's stock could go even...

Biotech Advancements in Innovative Cancer Therapy Reveal Developing Systemic Treatment Options - Company Receives Recommendation from World Health Organization for Lead Drug Candidate
PR Newswire - Thu Sep 04, 7:15AM CDT
Biotech companies seeking to make progress with Hepatocellular Carcinoma (HCC) therapies and other cancer therapeutics: GenSpera Inc. (OTC: GNSZ), Roche Holding AG (OTC: RHHBY), Eli Lilly and Company (NYSE: LLY), Amgen Inc. (NASDAQ: AMGN), Johnson and Johnson (NYSE: JNJ) and Infinity Pharmaceuticals Inc. (NASDAQ: INFI)

Infinity Pharma (INFI) Shares Skyrocket on Cancer Drug Partnership - Stocks in the News
Zacks Research Staff - Zacks Investment Research - Wed Sep 03, 5:47PM CDT
Shares of Infinity Pharma (INFI) are up more than 40 percent thanks to news of a partnership with AbbVie for a new cancer drug.

Infinity, AbbVie team on drug
at Investor's Business Daily - Wed Sep 03, 5:36PM CDT
Small biotech Infinity Pharmaceuticals (INFI) agreed to develop its blood cancer drug duvelisib, currently in trial stage, with big pharma AbbVie (ABBV). The deal includes an upfront payment of $275 mil to Infinity, and up to $530 mil in milestone...

Revised GAAP earnings guidance for AbbVie Inc for the Financial Year ending December 31, 2014 and Third Quarter ending September 30, 2014; Confirms Adjusted Earnings Guidance
PR Newswire Europe - Wed Sep 03, 3:46PM CDT
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Sasol AGM Resolutions Passed in One Swift Swing

Updated Category News Views 0

Sasol's AGM Delivers Smooth Sailing for Shareholders Can't say I'm surprised, but Sasol's annual general meeting on the 13th of November went off without a hitch—unless, of course, you're one of those folks who just loves fireworks at these gatherings. The entire set of resolutions danced through with a resounding "Aye," making it one heck of a day for anyone banking on...

Continue Reading
Local Voices to Shape Mekong's Story in New Alliance

Updated Category News Views 284

Unpacking the New Storytelling Strategy Right off the bat, let's make it clear—this isn't just another run-of-the-mill environmental project announcement. When the National Geographic Society teams up with ThaiBev to empower Southeast Asian storytellers, they're not just waving around the usual conservation banner. Instead, they're betting on local voices to lead the...

Continue Reading
D-Wave Quantum Hit with Securities Fraud Lawsuit

Updated Category News Views 380

A Legal Quagmire for D-Wave Quantum Investors Securities fraud lawsuits are like light in a dark alley—you need them when the truth's been stashed out of sight, but they illuminate the dirty and damp parts of investment strategies nobody wants to talk about. Right now, D-Wave Quantum Inc. is smack dab in the middle of such litigious action. If you had the misfortune of...

Continue Reading
Fapon's MEDICA 2026 Bid: Game-Changer or Same Old?

Updated Category News Views 18

Fapon's Ambitious Pitch at MEDICA: A Real Deal? MEDICA 2026 sees Fapon stepping up, laden with flashy promises and hardened expertise. Set up in Düsseldorf, these folks are pushing their Local Manufacturing Solutions harder than a door-to-door vacuum seller. The main pitch? Bolstering local IVD production with their comprehensive tech transfer services. How many outfits...

Continue Reading
YONDELIS: Thai Approval Opens New Sarcoma Treatment Path

Updated Category News Views 210

New Hope for Thai Sarcoma Patients Alright, we’ve got some good news coming out of Thailand, folks. The Thai FDA just greenlit YONDELIS® (trabectedin) for those grappling with advanced soft tissue sarcoma (STS). Now, this isn’t your everyday drug release—it’s a clinical chess move packing potential for patients who’ve run out of other options. December 1st,...

Continue Reading
Mercari and Suruga-ya Forge U.S. Venture for Culture

Updated Category News Views 19

Japanese Pop Culture Gears Up for US Market Surge Alright, folks, what we’ve got here is another bold move in the cross-border e-commerce game. Mercari and Suruga-ya are teaming up to establish a joint venture over in the U.S. The goal? To further capitalize on the growing appetite for Japanese entertainment and hobby goods among us all stateside. Now, it’s no secret...

Continue Reading
KINGRVER Boosts RV Comfort with New Water Heater Lineup

Updated Category News Views 370

An Upgrade for the Open Road In the land of RV living, comfort is king—or in this case, KINGRVER. Dropping affordable upgrades for water heaters into the world of RVs, KINGRVER's CT6 lineup is like a warm hug on a chilly campsite morning. Whether you've pulled up to a wooded retreat or parked under the vast desert sky, having dependable hot water shouldn't be a gamble....

Continue Reading
Pan-Mass Challenge Gifts $80M to Dana-Farber for 2026

Updated Category News Views 358

A Momentous Gift in a Crunch Time for Cancer Research Biking and philanthropy might seem like an odd duo, but let me tell you, the Pan-Mass Challenge (PMC) is making that partnership look like peanut butter and jelly. This year, PMC rolled out a jaw-dropping $80 million gift to the Dana-Farber Cancer Institute. You heard right—eighty million smackeroos. Talk about going...

Continue Reading
Phoenix Contact Achieves Guinness Record in Wiring

Updated Category News Views 81

A Blitz of Wires and Innovation Boy, did Phoenix Contact shake things up in Blomberg. On a crisp November day, a group of fresh-faced first-year students pulled off something astounding—wiring 500 terminal blocks in a jaw-dropping 2 minutes and 20 seconds. This wasn’t just any effort; it was enough to earn them a shiny new Guinness World Record. What they did wasn’t...

Continue Reading
Sungrow's Keeper Family: Revolutionizing C&I Energy Storage

Updated Category News Views 44

The Next Level in Energy Storage Solutions Well, folks, Sungrow's got something up its sleeve that's shaking up the energy storage scene. They're calling it the 'Keeper Family,' and if you’re deep into commercial and industrial (C&I) energy storage, this might just be your ticket to topping those profit charts. Launched at the Global Energy Pioneer Summit 2026, their...

Continue Reading

Top 5 Most Recently Viewed Articles

BETR Faces Securities Fraud Actions Post-Misleading Statements

Updated Category News Views 123

Unpacking the Legal Drama Around BETR The tale of Better Home & Finance Holding Company (BETR) is like a roadside crash you can't help but stare at. We're talking big, ugly losses and a chance for investors who got roughed up to throw some punches back with a securities fraud class action. The legal honchos at Howard G. Smith's law office are rallying the troops. If...

Continue Reading
Dorian LPG Faces Market Challenges But Holds Strong Financials

Updated Category News Views 133

Dorian LPG Stock Performance Overview In a challenging market environment, Dorian LPG Ltd. (NYSE: LPG) stock has recently touched a 52-week low, with shares falling to $24.86. This significant drop highlights a broader trend in the industry, as the company grapples with headwinds leading to a troubling one-year change of -38.78%. Investors are closely monitoring the stock...

Continue Reading
Copenhagen Airports A/S Annual General Meeting Announcement

Updated Category News Views 115

Upcoming Annual General Meeting of Copenhagen Airports A/S Shareholders are invited to participate in the Annual General Meeting of Copenhagen Airports A/S. This important event will take place on the scheduled date and time, providing an opportunity for stakeholders to engage with the management and stay informed about the company's direction. Notice of Meeting Details...

Continue Reading
Important Notice for Shareholders of KinderCare Learning

Updated Category News Views 131

Key Notice for KinderCare Learning Companies, Inc. Shareholders The Gross Law Firm has issued a crucial notice directed at shareholders of KinderCare Learning Companies, Inc. (NYSE: KLC) regarding a class action lawsuit. This communication is particularly relevant to those who acquired shares during the designated class period. Shareholders are strongly encouraged to make...

Continue Reading
Discover the New Romantic Getaway at Cicada Resort Bali Ubud

Updated Category News Views 350

Welcome to Cicada Resort Bali Ubud Cicada Resort Bali Ubud, Autograph Collection, located in Sebatu's tranquil environment, extends a warm invitation to travelers seeking a romantic retreat. The resort has recently become part of the prestigious Autograph Collection, contributing to its expanding presence in the hospitality space. Embrace Nature and Culture Just a short...

Continue Reading